Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review

Jinyoung Kim; Chaiho Jeong; Jeongmin Lee; Jeonghoon Ha; Ki Hyun Baek; Seohyun Kim; Tai Joon An; Chan Kwon Park; Hyoung Kyu Yoon; Jeong Uk Lim

doi:10.1053/j.seminoncol.2023.09.002

Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review

Jinyoung Kim, Chaiho Jeong, Jeongmin Lee, Jeonghoon Ha, Ki Hyun Baek, Seohyun Kim, Tai Joon An, Chan Kwon Park, Hyoung Kyu Yoon, Jeong Uk Lim

Department of Internal Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

During the course of lung cancer progression, bone metastases occur in about 40% of patients. Common complications associated with bone metastases in lung cancer patients include musculoskeletal pain, pathologic fractures, spinal cord compression, and hypercalcemia. We discuss the efficacy of bone-modifying agents (BMAs) in reducing skeletal-related events (SREs) and improving cancer-related outcomes, particularly in patients with stage IV non–small-cell lung cancer with bone metastases. In addition, the combined effects of BMAs with radiotherapy or immunotherapy in reducing SREs in patients with lung cancer and bone metastases are explored.

Original language	English
Pages (from-to)	105-112
Number of pages	8
Journal	Seminars in Oncology
Volume	50
Issue number	3-5
DOIs	https://doi.org/10.1053/j.seminoncol.2023.09.002
State	Published - 1 Jun 2023

Bibliographical note

Publisher Copyright:
© 2023 Elsevier Inc.

Keywords

Bone density conservation agents
Lung cancer
Metastases
Osteoporosis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.seminoncol.2023.09.002

Cite this

@article{285bbefeabcc45f6b72f0cd4d416996c,

title = "Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review",

abstract = "During the course of lung cancer progression, bone metastases occur in about 40% of patients. Common complications associated with bone metastases in lung cancer patients include musculoskeletal pain, pathologic fractures, spinal cord compression, and hypercalcemia. We discuss the efficacy of bone-modifying agents (BMAs) in reducing skeletal-related events (SREs) and improving cancer-related outcomes, particularly in patients with stage IV non–small-cell lung cancer with bone metastases. In addition, the combined effects of BMAs with radiotherapy or immunotherapy in reducing SREs in patients with lung cancer and bone metastases are explored.",

keywords = "Bone density conservation agents, Lung cancer, Metastases, Osteoporosis",

author = "Jinyoung Kim and Chaiho Jeong and Jeongmin Lee and Jeonghoon Ha and Baek, {Ki Hyun} and Seohyun Kim and An, {Tai Joon} and Park, {Chan Kwon} and Yoon, {Hyoung Kyu} and Lim, {Jeong Uk}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = jun,

day = "1",

doi = "10.1053/j.seminoncol.2023.09.002",

language = "English",

volume = "50",

pages = "105--112",

journal = "Seminars in Oncology",

issn = "0093-7754",

publisher = "W.B. Saunders",

number = "3-5",

}

TY - JOUR

T1 - Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors

T2 - A narrative review

AU - Kim, Jinyoung

AU - Jeong, Chaiho

AU - Lee, Jeongmin

AU - Ha, Jeonghoon

AU - Baek, Ki Hyun

AU - Kim, Seohyun

AU - An, Tai Joon

AU - Park, Chan Kwon

AU - Yoon, Hyoung Kyu

AU - Lim, Jeong Uk

PY - 2023/6/1

Y1 - 2023/6/1

N2 - During the course of lung cancer progression, bone metastases occur in about 40% of patients. Common complications associated with bone metastases in lung cancer patients include musculoskeletal pain, pathologic fractures, spinal cord compression, and hypercalcemia. We discuss the efficacy of bone-modifying agents (BMAs) in reducing skeletal-related events (SREs) and improving cancer-related outcomes, particularly in patients with stage IV non–small-cell lung cancer with bone metastases. In addition, the combined effects of BMAs with radiotherapy or immunotherapy in reducing SREs in patients with lung cancer and bone metastases are explored.

AB - During the course of lung cancer progression, bone metastases occur in about 40% of patients. Common complications associated with bone metastases in lung cancer patients include musculoskeletal pain, pathologic fractures, spinal cord compression, and hypercalcemia. We discuss the efficacy of bone-modifying agents (BMAs) in reducing skeletal-related events (SREs) and improving cancer-related outcomes, particularly in patients with stage IV non–small-cell lung cancer with bone metastases. In addition, the combined effects of BMAs with radiotherapy or immunotherapy in reducing SREs in patients with lung cancer and bone metastases are explored.

KW - Bone density conservation agents

KW - Lung cancer

KW - Metastases

KW - Osteoporosis

UR - http://www.scopus.com/inward/record.url?scp=85171265207&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2023.09.002

DO - 10.1053/j.seminoncol.2023.09.002

M3 - Review article

C2 - 37723018

AN - SCOPUS:85171265207

SN - 0093-7754

VL - 50

SP - 105

EP - 112

JO - Seminars in Oncology

JF - Seminars in Oncology

IS - 3-5

ER -

Bone-modifying agents for non–small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this